Michael Joseph Satlin MD

Instructor, Medicine, Weill Cornell Medical College

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2008
University of Virginia School of MedicineClass of 2005

PubMed

Untargeted metabolomics reveals organism specific biomarkers of carbapenem resistance in Klebsiella pneumoniae and Escherichia coli.
Nicholas Bartelo, Yaxin Li, Ying Hao, Vijay Soni, Jamie Marino
NPJ Systems Biology and Applications. 2026-05-26
Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study.
Anders Østergaard Petersen, Birgitte Damholt, Mette Grove, Jonas Hink, Tamara Marotte-Hurbon
The Lancet. Microbe. 2026-04-01
1 citations
Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections.
Natalie A Mackow, Wanying Shao, Lizhao Ge, Lauren Komarow, Jianping Jiang
Clinical Infectious Diseases. 2026-03-06

Journal Articles

Incidence, Significance, and Persistence of Human Coronavirus Infection in Hematopoietic Stem Cell Transplant Recipients
Catherine B Small, Rosemary Soave, Dana Zappetti, Michael J Satlin, Emily M Eichenberger, Tsiporah Shore, Nature
Gut Microbiota Dysbiosis and Diarrhea in Kidney Transplant Recipients
Eric Pamer, Manikkam Suthanthiran, Ying Taur, Michael J Satlin, Darshana Dadhania, John Richard Lee, Carl Crawford, Michelle Lubetzky, American journal of transplantation

Abstracts/Posters

Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy
Michael Satlin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Polymyxin B and Fosfomycin Thwart KPC-Producing Klebsiella Pneumoniae in the Hollow Fibre Infection ModelFebruary 2018
Polymyxin B and Fosfomycin Thwart KPC-Producing Klebsiella Pneumoniae in the Hollow Fibre Infection ModelFebruary 2018

Shionogi to Present in Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETCROJA® (Cefiderocol) Against Gram-Negative PathogensSeptember 29th, 2021
$750K Awarded for Intercampus ResearchMarch 2nd, 2021
COVID-19 Viral Load Could Help Physicians Predict Illness SeverityDecember 29th, 2020

Screening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic PatientsWEILL MEDICAL COLL OF CORNELL UNIV2024–2026
Screening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic PatientsWEILL MEDICAL COLL OF CORNELL UNIV2024–2026
Screening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic PatientsWEILL MEDICAL COLL OF CORNELL UNIV2020–2025

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
Great West PPO
HealthAmerica HealthAssurance PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment